Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992755 · ClinicalTrials.gov registry record · Phase 3
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
A Phase 3 study of Primary Pulmonary Hypertension, sponsored by Liquidia Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT03992755 is a Phase 3 study of Primary Pulmonary Hypertension that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 92 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03992755, a Phase 3 study of Primary Pulmonary Hypertension, is active but no longer recruiting, sponsored by Liquidia Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Conditions Studied
Interventions
- DRUG LIQ861 Inhaled Treprostinil
Study Locations (20)
California
- West Los Angeles VA Healthcare Center - Los Angeles
- UC Davis Medical Center - Sacramento
- Los Angeles Biomedical Research Center - Torrance
Florida
- University of Florida - Gainesville
- Mayo Clinic-Jacksonville - Jacksonville
- AdventHealth - Orlando
Arizona
- Banner University Medical Center - Phoenix
- Arizona Pulmonary Specialists, Ltd. - Phoenix
Illinois
- Northwestern Medicine, Feinberg School of Medicine - Chicago
- University of Chicago Medicine - Chicago
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Ochsner Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992755
The ClinicalTrials.gov registry entry for NCT03992755 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LIQ861 Inhaled Treprostinil is the first listed.
NCT03992755 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03992755 about?
NCT03992755 is a clinical study titled "Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil". The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT03992755?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2019-07-18. Estimated completion is 2025-05-31.
What conditions does trial NCT03992755 study?
This clinical trial studies the following conditions: Primary Pulmonary Hypertension.
What interventions are being tested in trial NCT03992755?
The interventions under investigation include: LIQ861 Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT03992755?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992755 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.